Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level
Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level
This study is designed in order to investigate the effect of cinacalcet in combination with
 routine conventional medical management for treatment of secondary hyperparathyroidism (SHPT)
 and Ca, P control. This study will compare the efficacy of a cinacalcet-based regimen with
 unrestricted conventional care (vitamin D and phosphate binders) for achieving the stringent
 National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) targets for
 dialysis patients.
Inclusion Criteria:

 -  Peritoneal dialysis patients with secondary HPT(iPTH > 300 pg/mL)

 -  > 18 yr of age, < 70

 -  had receive PD for > 3 mo,

 -  intact PTH level > 300 pg/ml and <1000 pg/ml

 -  albumin corrected Ca level >= 9.0 mg/dL

 Exclusion Criteria:

 -  pregnant or breast-feeding,

 -  had undergone parathyroidectomy within previous 3 mo,

 -  are involved in other clinical trial within 30 d

 -  had received cinacalcet therapy previously.